Results 31 to 40 of about 15,148 (196)

Drosophila Cancer Models Identify Functional Differences between Ret Fusions

Cell Reports, 2016
We generated and compared Drosophila models of RET fusions CCDC6-RET and NCOA4-RET. Both RET fusions directed cells to migrate, delaminate, and undergo EMT, and both resulted in lethality when broadly expressed.
Sarah Levinson, Ross L. Cagan
doaj   +1 more source

Pralsetinib treatment for multiple fusions in lung adenocarcinoma: a case report

Journal of International Medical Research, 2022
Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection ( RET ) fusions occur in 1% to 2% of lung cancer patients. Pralsetinib has been used
Xiangming Cao, Xiongwei Liu, Simin Wang, Zhen Liu, Xin Ren, Debin Sun, Lichun Deng   +6 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Deciphering the Photopolymerization‐Induced Nanostructures and Interface Formation for Submicrometer Additive Manufacturing

Advanced Functional Materials, EarlyView.
This work reveals the UV‐curing‐induced monomer‐rich domain, oligomer‐rich domain, and entangled oligomer domain. The cured submicron films in stressed state induce interlayer nano‐wrinkle structures during the deposition of the second layer. Stress‐free cured films in relaxed state form non‐diffusive, diffusive and semi‐diffusive interlayer ...
Shouzheng Chen, Yufeng Zhai, Jungui Zhou, Lixing Li, Simon Schraad, Guangjiu Pan, Xuehe Jiang, Sarathlal Koyiloth Vayalil, Rolf A. T. M. van Benthem, Julien R. G. Navarro, Johan F. G. A. Jansen, Mats K. G. Johansson, Peter Müller‐Buschbaum, Stephan V. Roth   +13 more
wiley   +1 more source

A Hybrid Bioprinting–Microfabrication Approach to Controllable Multitype Spheroid Arrays for Modeling Tumor Heterogeneity

Advanced Healthcare Materials, EarlyView.
This work introduces a “cancer‐in‐a‐well” technology that recreates tumor heterogeneity in vitro using multitype spheroid arrays. Combining bioprinting/microdispensing with microstructured culture devices, the system improves drug screening and modeling of tumor complexity.
Simone Bonetti, Eva Clemente, Emanuela Mensà, Marco de Maria, Fulvia Farabegoli, Emanuela Saracino, Barbara Bortolani, Emanuela Marcelli, Renato Brandimarti, Dario de Biase, Giampaolo Zuccheri   +10 more
wiley   +1 more source

Intelligent Sky Guardians (InSkyGuard): An Aerial Robotic Swarm for Autonomous Detection and Entrapment of Rogue Multirotors

Advanced Robotics Research, EarlyView.
Intelligent Sky Guardians (InSkyGuard) is introduced as a four‐drone swarm that autonomously detects, tracks, and safely captures rogue drones using a coordinated net system. Computer vision and leader–follower control architecture enable synchronized enclosure, while integrated failsafes enhance system reliability. Validated through closed‐environment
Joshua Hastings, Levanya Dewanarayana, Iline Shaju, Haider Al‐Wizni, Sampson Marquis, Weicheng Huang, Pooya Sareh   +6 more
wiley   +1 more source

Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report

JTO Clinical and Research Reports
RET fusions are present in 1% to 2% of NSCLCs. Although RET inhibitors like selpercatinib are effective, resistance inevitably develops. We present the case of a 28-year-old female with recurrent NSCLC and a CCDC6::RET fusion treated with selpercatinib ...
Jacobi B. Hines, MD, Benjamin C. Bowar, PharmD, Margaret Colleton, MMS, Lydia Chelala, MD, Peng Wang, MD, Angad A. Chadha, MD, Jeremy Segal, MD, Christine M. Bestvina, MD   +7 more
doaj   +1 more source

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

BMC Cancer, 2019
Background Genetic alterations, including mutation of epidermal growth factor receptor or v-Ki-ras2 kirsten rat sarcoma viral oncogene homolog and fusion of anaplastic lymphoma kinase (ALK), RET proto-oncogene (RET), or v-ros UR2 sarcoma virus oncogene ...
Koh Furugaki, Marie Mochizuki, Mirei Kohno, Sei Shu, Naoki Harada, Yasushi Yoshimura   +5 more
doaj   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced fusion-positive non-small-cell lung cancer and thyroid cancer, and -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Therapeutic Advances in Medical Oncology, 2023
Background: Patient-reported outcomes (PROs) are increasingly becoming an important part of clinical trials as they are helpful in analyzing the safety and efficacy of treatment in chronic diseases like cancer.
Shun Lu, Xiangqian Zheng, Yuping Sun, Dingzhi Huang, Lin Wu, Qinghai Ji, Chengzhi Zhou, Jianying Zhou, Ye Guo, Minghua Ge, Ding Ding, Jingxin Shao, Wanli Zhang, Ming Gao, Ying Cheng   +14 more
doaj   +1 more source